IL6 and nonpapillary renal cell carcinoma: Therefore, therapies targeting TTC13 as well as IL6-JAK-STAT3 signaling pathway may benefit ccRCC patients by simultaneously suppressing tumor cell growth and stimulating anti-tumor immunity.